# EDGAR Filing Document

**Accession Number:** 0001087294
**File Stem:** 0001628280-25-029849
**Filing Date:** 2025-6
**Character Count:** 7442
**Document Hash:** f64e5aafa121ee5618ca9ca3a03ec9af
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001628280-25-029849.hdr.sgml**: 20250606

**ACCESSION NUMBER**: 0001628280-25-029849

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20250501

**FILED AS OF DATE**: 20250606

**DATE AS OF CHANGE**: 20250606

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** KAZIMI A J
- **CENTRAL INDEX KEY:** 0001075050

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-33637
- **FILM NUMBER:** 251028973

**MAIL ADDRESS:**
- **STREET 1:** 1207 17TH AVENUE SUITE 103
- **CITY:** NASHVILLE
- **STATE:** TN
- **ZIP:** 37212
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** CUMBERLAND PHARMACEUTICALS INC
- **CENTRAL INDEX KEY:** 0001087294
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 2525 WEST END AVENUE
- **STREET 2:** SUITE 950
- **CITY:** NASHVILLE,
- **STATE:** TN
- **ZIP:** 37203
- **BUSINESS PHONE:** 615-255-0068

**MAIL ADDRESS:**
- **STREET 1:** 2525 WEST END AVENUE
- **STREET 2:** SUITE 950
- **CITY:** NASHVILLE
- **STATE:** TN
- **ZIP:** 37203

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[x] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>KAZIMI A J<br><sub>(Last) (First) (Middle)</sub><br>1600 WEST END AVE.<br>SUITE 1300<br><sub>(Street)</sub><br>NASHVILLE, TN 37203<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2025-05-01 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[X] Director [X] 10% Owner<br>[X] Officer (give title below) [ ] Other (specify below)<br>_Chairman and CEO_ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>CUMBERLAND PHARMACEUTICALS INC [ CPIX ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| Common Stock | 2025-05-01 |  | P | V | 8<sup>(1)</sup> | A | $4.86 | 5699100 | D |  |
| Common Stock | 2025-05-02 |  | P | V | 8<sup>(1)</sup> | A | $4.75 | 5699108 | D |  |
| Common Stock | 2025-05-05 |  | P | V | 8<sup>(1)</sup> | A | $4.68 | 5699116 | D |  |
| Common Stock | 2025-05-06 |  | P | V | 8<sup>(1)</sup> | A | $4.60 | 5699124 | D |  |
| Common Stock | 2025-05-07 |  | P | V | 8<sup>(1)</sup> | A | $4.71 | 5699132 | D |  |
| Common Stock | 2025-05-08 |  | P | V | 8<sup>(1)</sup> | A | $4.50 | 5699140 | D |  |
| Common Stock | 2025-05-09 |  | P | V | 8<sup>(1)</sup> | A | $4.78 | 5699148 | D |  |
| Common Stock | 2025-05-12 |  | P | V | 8<sup>(1)</sup> | A | $5.25 | 5699156 | D |  |
| Common Stock | 2025-05-13 |  | P | V | 8<sup>(1)</sup> | A | $5.67 | 5699164 | D |  |
| Common Stock | 2025-05-14 |  | P | V | 8<sup>(1)</sup> | A | $5.68 | 5699172 | D |  |
| Common Stock | 2025-05-15 |  | P | V | 8<sup>(1)</sup> | A | $5.20 | 5699180 | D |  |
| Common Stock | 2025-05-16 |  | P | V | 8<sup>(1)</sup> | A | $5.37 | 5699188 | D |  |
| Common Stock | 2025-05-19 |  | P | V | 8<sup>(1)</sup> | A | $4.92 | 5699196 | D |  |
| Common Stock | 2025-05-20 |  | P | V | 8<sup>(1)</sup> | A | $5.41 | 5699204 | D |  |
| Common Stock | 2025-05-21 |  | P | V | 8<sup>(1)</sup> | A | $5.05 | 5699212 | D |  |
| Common Stock | 2025-05-22 |  | P | V | 8<sup>(1)</sup> | A | $5.10 | 5699220 | D |  |
| Common Stock | 2025-05-23 |  | P | V | 8<sup>(1)</sup> | A | $5.14 | 5699228 | D |  |
| Common Stock | 2025-05-27 |  | P | V | 8<sup>(1)</sup> | A | $5.27 | 5699236 | D |  |
| Common Stock | 2025-05-28 |  | P | V | 8<sup>(1)</sup> | A | $5.68 | 5699244 | D |  |
| Common Stock | 2025-05-29 |  | P | V | 8<sup>(1)</sup> | A | $5.66 | 5699252 | D |  |
| Common Stock | 2025-05-30 |  | P | V | 8<sup>(1)</sup> | A | $4.93 | 5699260 | D |  |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |

---

### Footnotes:

(1) The reported purchase occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 14, 2024.

**Signature:** A.J. Kazimi by /s/ John Hamm as attorney-in-fact  
**Date:** 2025-06-06

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**